Not Applicable
1. Field of the Invention
The present invention relates generally to the lowering and control of the temperature of the human body. More particularly, the invention relates to a method and intravascular apparatus for cooling the whole body, especially during periods of fever.
2. Background Information
Organs in the human body, such as the brain, kidney and heart, are maintained at a constant temperature of approximately 37° C. Hypothermia can be clinically defined as a core body temperature of 35° C. or less. Hypothermia is sometimes characterized further according to its severity. A body core temperature in the range of 33° C. to 35° C. is described as mild hypothermia. A body temperature of 28° C. to 32° C. is described as moderate hypothermia. A body core temperature in the range of 24° C. to 28° C. is described as severe hypothermia.
Hypothermia is uniquely effective in reducing brain injury caused by a variety of neurological insults and may eventually play an important role in emergency brain resuscitation. Experimental evidence has demonstrated that cerebral cooling improves outcome after global ischemia, focal ischemia, or traumatic brain injury. For this reason, hypothermia may be induced in order to reduce the effect of certain bodily injuries to the brain as well as other organs.
Cerebral hypothermia has traditionally been accomplished through whole body cooling to create a condition of total body hypothermia in the range of 20° C. to 30° C. The currently-employed techniques and devices used to cause total body hypothermia lead to various side effects. In addition to the undesirable side effects, present methods of administering total body hypothermia are cumbersome.
Catheters have been developed which are inserted into the bloodstream of the patient in order to induce total body hypothermia. For example, U.S. Pat. No. 3,425,419 to Dato describes a method and apparatus of lowering and raising the temperature of the human body. Dato induces moderate hypothermia in a patient using a rigid metallic catheter. The catheter has an inner passageway through which a fluid, such as water, can be circulated. The catheter is inserted through the femoral vein and then through the inferior vena cava as far as the right atrium and the superior vena cava. The Dato catheter has an elongated cylindrical shape and is constructed from stainless steel. By way of example, Dato suggests the use of a catheter approximately 70 cm in length and approximately 6 mm in diameter. Thus, the Dato device cools along the length of a very elongated device. Use of the Dato device is highly cumbersome due to its size and lack of flexibility.
U.S. Pat. No. 5,837,003 to Ginsburg also discloses a method and apparatus for controlling a patient's body temperature. In this technique, a flexible catheter is inserted into the femoral artery or vein or the jugular vein. The catheter may be in the form of a balloon to allow an enhanced surface area for heat transfer. A thermally conductive metal foil may be used as part of a heat-absorbing surface. This device fails to disclose or teach use of any ability to enhance heat transfer. In addition, the disclosed device fails to disclose temperature regulation.
An ailment particular susceptible to treatment by cooling, either selective or whole body, is fever or hyperthermia. There is a growing awareness of the dangers associated with fever. Many patients, especially after surgery and/or in the intensive care unit, suffer from fever. For example, it is estimated that 90% of patients in neurointensive care units suffering from sub-arachnoid hemorrhage have a fever. Further, 60% of patients in neurointensive care units suffering from intra-cranial hemorrhage have a fever. 80% of patients in neurointensive care units suffering from traumatic brain injury have a fever. These patients are typically treated with Tylenol, cooling blankets, or other such methods. These methods are not believed to be very effective; moreover, they are difficult to control.
Therefore, a practical method and apparatus that lowers and controls the temperature of the human body satisfies a long-felt need.
In one aspect, the apparatus of the present invention can include a heat transfer element that can be used to apply cooling to the blood flowing in a large vein feeding the heart.
The heat transfer element, by way of example only, includes first and second elongated, articulated segments, each segment having a mixing-inducing exterior surface. A flexible joint can connect the first and second elongated segments. An inner lumen may be disposed within the first and second elongated segments and is capable of transporting a pressurized working fluid to a distal end of the first elongated segment. In addition, the first and second elongated segments may have a mixing-inducing interior surface for inducing mixing within the pressurized working fluid. The mixing-inducing exterior surface may be adapted to induce mixing within a blood flow when placed within an artery or vein. In one embodiment, the flexible joint includes a bellows section that also allows for axial compression of the heat transfer element as well as for enhanced flexibility. In alternative embodiments, the bellows section may be replaced with flexible tubing such as small cylindrical polymer connecting tubes.
In one embodiment, the mixing-inducing exterior surfaces of the heat transfer element include one or more helical grooves and ridges. Adjacent segments of the heat transfer element can be oppositely spiraled to increase mixing. For instance, the first elongated heat transfer segment may include one or more helical ridges having a counter-clockwise twist, while the second elongated heat transfer segment includes one or more helical ridges having a clockwise twist. Alternatively, of course, the first elongated heat transfer segment may include one or more clockwise helical ridges, and the second elongated heat transfer segment may include one or more counter-clockwise helical ridges. The first and second elongated, articulated segments may be formed from highly conductive materials such as metals, thin polymers, or doped polymers.
The heat transfer device may also have a supply catheter with an inner catheter lumen coupled to the inner lumen within the first and second elongated heat transfer segments. A working fluid supply configured to dispense the pressurized working fluid may be coupled to the inner catheter lumen or alternatively to the supply catheter. The working fluid supply may be configured to produce the pressurized working fluid at a temperature of about 0° C. and at a pressure below about 5 atmospheres of pressure.
In yet another alternative embodiment, the heat transfer device may have three or more elongated, articulated, heat transfer segments each having a mixing-inducing exterior surface, with additional flexible joints connecting the additional elongated heat transfer segments. In one such embodiment, by way of example only, the first and third elongated heat transfer segments may include clockwise helical ridges, and the second elongated heat transfer segment may include one or more counter-clockwise helical ridges. Alternatively, of course, the first and third elongated heat transfer segments may include counter-clockwise helical ridges, and the second elongated heat transfer segment may include one or more clockwise helical ridges.
The mixing-inducing exterior surface of the heat transfer element may optionally include a surface coating or treatment to inhibit clot formation. A surface coating may also be used to provide a degree of lubricity to the heat transfer element and its associated catheter.
The present invention is also directed to a method of treating fever in the body by inserting a flexible cooling element into a vein that is in pressure communication with the heart, e.g., the femoral or iliac veins, the superior or inferior vena cavae or both. The vena cavae may be accessed via known techniques from the jugular vein or from the subclavian or femoral veins, for example. The heat transfer element in one or both vena cavae may then cool virtually all the blood being returned to the heart. The cooled blood enters the right atrium at which point the same is pumped through the right ventricle and into the pulmonary artery to the lungs where the same is oxygenated. Due to the heat capacity of the lungs, the blood does not appreciably warm during oxygenation. The cooled blood is returned to the heart and pumped to the entire body via the aorta. Thus, cooled blood may be delivered indirectly to a chosen organ such as the brain. This indirect cooling is especially effective as high blood flow organs such as the heart and brain are preferentially supplied blood by the vasculature.
A warming blanket or other warming device may be applied to portions of the body to provide comfort to the patient and to inhibit thermoregulatory responses such as vasoconstriction. Thermoregulatory drugs may also be so provided for this reason.
The method further includes circulating a working fluid through the flexible, conductive cooling element in order to lower the temperature of the blood in the vena cava. The flexible, conductive heat transfer element preferably absorbs more than about 100 or 300 Watts of heat.
The method may also include inducing mixing within the free stream blood flow within the vena cava. It is noted that a degree of turbulence or mixing is generally present within the vena cava anyway. The step of circulating may include inducing mixing in the flow of the working fluid through the flexible heat transfer element. The pressure of the working fluid may be maintained below about 5 atmospheres of pressure.
The present invention also envisions a method for lowering a fever in the body of a patient which includes introducing a catheter, with a cooling element, into a vena cava supplying the heart, the catheter having a diameter of about 18 mm or less, inducing mixing in blood flowing over the cooling element, and lowering the temperature of the cooling element to remove heat from the blood to cool the blood. In one embodiment, the cooling step removes at least about 50 Watts of heat from the blood. The mixing induced may result in a Nusselt number enhancement of the flow of between about 5 and 80.
Advantages of the invention are numerous. Patients can be provided with an efficient method of reducing fever that does not suffer from the deleterious consequences of the prior art. The procedure can be administered safely and easily. Numerous cardiac and neural settings can benefit by the hypothermic therapy. Other advantages will be understood from the following.
The novel features of this invention, as well as the invention itself, will be best understood from the attached drawings, taken along with the following description, in which similar reference characters refer to similar parts, and in which:
Overview
A one or two-step process and a one or two-piece device may be employed to intravascularly lower the temperature of a body in order to treat fever. A cooling element may be placed in a high-flow vein such as the vena cavae to absorb heat from the blood flowing into the heart. This transfer of heat causes a cooling of the blood flowing through the heart and thus throughout the vasculature. Such a method and device may therapeutically be used to treat fever.
A heat transfer element that systemically cools blood should be capable of providing the necessary heat transfer rate to produce the desired cooling effect throughout the vasculature. This may be up to or greater than 300 watts, and is at least partially dependent on the mass of the patient and the rate of blood flow. Surface features may be employed on the heat transfer element to enhance the heat transfer rate. The surface features and other components of the heat transfer element are described in more detail below.
One problem with treating fever with cooling is that the cause of the patient's fever attempts to defeat the cooling. Thus, a high power device is often required.
Anatomical Placement
The internal jugular vein is the vein that directly drains the brain. The external jugular joins the internal jugular at the base of the neck. The internal jugular veins join the subclavian veins to form the brachiocephalic veins that in turn drain into the superior vena cava. The superior vena cava drains into the right atrium of the heart and supplies blood to the heart from the upper part of the body.
A cooling element may be placed into the superior vena cava, inferior vena cava, or otherwise into a vein which feeds into the superior vena cava or otherwise into the heart to cool the body. A physician may percutaneously place the catheter into the subclavian or internal or external jugular veins to access the superior vena cava. The blood, cooled by the heat transfer element, may be processed by the heart and provided to the body in oxygenated form to be used as a conductive medium to cool the body. The lungs have a fairly low heat capacity, and thus the lungs do not cause appreciable rewarming of the flowing blood.
The vasculature by its very nature provides preferential blood flow to the high blood flow organs such as the brain and the heart. Thus, these organs are preferentially cooled by such a procedure. The core body temperature may be measured by an esophageal probe. The brain temperature usually decreases more rapidly than the core body temperature. The inventors believe this effect to be due to the preferential supply of blood provided to the brain and heart. This effect may be even more pronounced if thermoregulatory effects, such as vasoconstriction, occur that tend to focus blood supply to the core vascular system and away from the peripheral vascular system.
Heat Transfer
When a heat transfer element is inserted approximately coaxially into an artery or vein, the primary mechanism of heat transfer between the surface of the heat transfer element and the blood is forced convection. Convection relies upon the movement of fluid to transfer heat. Forced convection results when an external force causes motion within the fluid. In the case of arterial or venous flow, the beating heart causes the motion of the blood around the heat transfer element.
The magnitude of the heat transfer rate is proportional to the surface area of the heat transfer element, the temperature differential, and the heat transfer coefficient of the heat transfer element.
The receiving artery or vein into which the heat transfer element is placed has a limited diameter and length. Thus, the surface area of the heat transfer element must be limited to avoid significant obstruction of the artery or vein and to allow the heat transfer element to easily pass through the vascular system. For placement within the superior vena cava via the external jugular, the cross sectional diameter of the heat transfer element may be limited to about 5–6 mm, and its length may be limited to approximately 10–15 cm. For placement within the inferior vena cava, the cross sectional diameter of the heat transfer element may be limited to about 6–7 mm, and its length may be limited to approximately 25–35 cm.
Decreasing the surface temperature of the heat transfer element can increase the temperature differential. However, the minimum allowable surface temperature is limited by the characteristics of blood. Blood freezes at approximately 0° C. When the blood approaches freezing, ice emboli may form in the blood, which may lodge downstream, causing serious ischemic injury. Furthermore, reducing the temperature of the blood also increases its viscosity, which results in a small decrease in the value of the convection heat transfer coefficient. In addition, increased viscosity of the blood may result in an increase in the pressure drop within the artery, thus compromising the flow of blood to the brain. Given the above constraints, it is advantageous to limit the minimum allowable surface temperature of the cooling element to approximately 5° C. This results in a maximum temperature differential between the blood stream and the cooling element of approximately 32° C. For other physiological reasons, there are limits on the maximum allowable surface temperature of the warming element.
However, in certain situations, temperatures lower than 0° C. may be used. For example, certain patients may have blood flows such that the flow per se prohibits or significantly inhibits freezing. To achieve such cooling, sub-zero temperatures may be used. In these cases, working fluids such as perfluorocarbons may be employed.
The mechanisms by which the value of the convection heat transfer coefficient may be increased are complex. However, it is well known that the convection heat transfer coefficient increases with the level of “mixing” or “turbulent” kinetic energy in the fluid flow. Thus it is advantageous to have blood flow with a high degree of mixing in contact with the heat transfer element.
The blood flow has a considerably more stable flux in the vena cava than in an artery. However, the blood flow in the vena cava still has a high degree of inherent mixing or turbulence. Reynolds numbers in the superior vena cava may range, for example, from 2,000 to 5,000. Thus, blood cooling in the vena cava may benefit from enhancing the level of mixing with the heat transfer element but this benefit may be substantially less than that caused by the inherent mixing.
Boundary Layers
A thin boundary layer has been shown to form during the cardiac cycle. Boundary layers develop adjacent to the heat transfer element as well as next to the walls of the artery or vein. Each of these boundary layers has approximately the same thickness as the boundary layer that would have developed at the wall of the artery in the absence of the heat transfer element. The free stream flow region is developed in an annular ring around the heat transfer element. The heat transfer element used in such a vessel should reduce the formation of such viscous boundary layers.
Heat Transfer Element Characteristics and Description
The intravascular heat transfer element should be flexible in order to be placed within the vena cavae or other veins or arteries. The flexibility of the heat transfer element is an important characteristic because the same is typically inserted into a vein such as the external jugular and accesses the vena cava by initially passing though a series of one or more branches. Further, the heat transfer element is ideally constructed from a highly thermally conductive material such as metal in order to facilitate heat transfer. The use of a highly thermally conductive material increases the heat transfer rate for a given temperature differential between the working fluid within the heat transfer element and the blood. This facilitates the use of a higher temperature coolant, or lower temperature warming fluid, within the heat transfer element, allowing safer working fluids, such as water or saline, to be used. Highly thermally conductive materials, such as metals, tend to be rigid. Therefore, the design of the heat transfer element should facilitate flexibility in an inherently inflexible material.
However, balloon designs may also be employed, such as those disclosed in co-pending U.S. patent application Ser. No. 09/215,038, filed Dec. 16, 1998, entitled “Inflatable Catheter for Selective Organ Heating and Cooling and Method of Using the Same,”, now U.S. Pat. No. 6,261,312 and incorporated herein by reference in its entirety.
It is estimated that the cooling element should absorb at least about 50 Watts of heat when placed in the vena cava to lower the temperature of the body to between about 30° C. and 34° C. These temperatures are thought to be appropriate to lower most fevers. The power removed determines how quickly the target temperature can be reached. For example, in a fever therapy in which it is desired to lower brain temperature, the same may be lowered about 4° C. per hour in a 70 kg human upon removal of 300 Watts.
One embodiment of the invention uses a modular design. This design creates helical blood flow and produces a level of mixing in the blood flow by periodically forcing abrupt changes in the direction of the helical blood flow. The abrupt changes in flow direction are achieved through the use of a series of two or more heat transfer segments, each included of one or more helical ridges. The use of periodic abrupt changes in the helical direction of the blood flow in order to induce strong free stream turbulence may be illustrated with reference to a common clothes washing machine. The rotor of a washing machine spins initially in one direction causing laminar flow. When the rotor abruptly reverses direction, significant turbulent kinetic energy is created within the entire wash basin as the changing currents cause random turbulent motion within the clothes-water slurry. These surface features also tend to increase the surface area of the heat transfer element, further enhancing heat transfer.
The first heat transfer segment 20 is coupled to a second elongated heat transfer segment 22 by a first bellows section 25, which provides flexibility and compressibility. The second heat transfer segment 22 includes one or more helical ridges 32 with one or more helical grooves 30 therebetween. The ridges 32 and grooves 30 have a right hand, or clockwise, twist as they proceed toward the distal end of the heat transfer segment 22. The second heat transfer segment 22 is coupled to a third elongated heat transfer segment 24 by a second bellows section 27. The third heat transfer segment 24 includes one or more helical ridges 36 with one or more helical grooves 34 therebetween. The helical ridge 36 and the helical groove 34 have a left hand, or counter-clockwise, twist as they proceed toward the distal end of the heat transfer segment 24. Thus, successive heat transfer segments 20, 22, 24 of the heat transfer element 14 alternate between having clockwise and counterclockwise helical twists. The actual left or right hand twist of any particular segment is immaterial, as long as adjacent segments have opposite helical twist.
In addition, the rounded contours of the ridges 28, 32, 36 allow the heat transfer element 14 to maintain a relatively atraumatic profile, thereby minimizing the possibility of damage to the blood vessel wall. A heat transfer element according to the present invention may include two, three, or more heat transfer segments.
The bellows sections 25, 27 are formed from seamless and nonporous materials, such as metal, and therefore are impermeable to gas, which can be particularly important, depending on the type of working fluid that is cycled through the heat transfer element 14. The structure of the bellows sections 25, 27 allows them to bend, extend and compress, which increases the flexibility of the heat transfer element 14 so that it is more readily able to navigate through blood vessels. The bellows sections 25, 27 also provide for axial compression of the heat transfer element 14, which can limit the trauma when the distal end of the heat transfer element 14 abuts a blood vessel wall. The bellows sections 25, 27 are also able to tolerate cryogenic temperatures without a loss of performance. In alternative embodiments, the bellows may be replaced by flexible polymer tubes, which are bonded between adjacent heat transfer segments.
The exterior surfaces of the heat transfer element 14 can be made from metal, and may include very high thermal conductivity materials such as nickel, thereby facilitating heat transfer. Alternatively, other metals such as stainless steel, titanium, aluminum, silver, copper and the like, can be used, with or without an appropriate coating or treatment to enhance biocompatibility or inhibit clot formation. Suitable biocompatible coatings include, e.g., gold, platinum or polymer paralyene. The heat transfer element 14 may be manufactured by plating a thin layer of metal on a mandrel that has the appropriate pattern. In this way, the heat transfer element 14 may be manufactured inexpensively in large quantities, which is an important feature in a disposable medical device.
Because the heat transfer element 14 may dwell within the blood vessel for extended periods of time, such as 24–48 hours or even longer, it may be desirable to treat the surfaces of the heat transfer element 14 to avoid clot formation. In particular, one may wish to treat the bellows sections 25, 27 because stagnation of the blood flow may occur in the convolutions, thus allowing clots to form and cling to the surface to form a thrombus. One means by which to prevent thrombus formation is to bind an antithrombogenic agent to the surface of the heat transfer element 14. For example, heparin is known to inhibit clot formation and is also known to be useful as a biocoating. Alternatively, the surfaces of the heat transfer element 14 may be bombarded with ions such as nitrogen. Bombardment with nitrogen can harden and smooth the surface and thus prevent adherence of clotting factors. Another coating that provides beneficial properties may be a lubricious coating. Lubricious coatings, on both the heat transfer element and its associated catheter, allow for easier placement in the, e.g., vena cava.
It is important to note that the same mechanisms that govern the heat transfer rate between the exterior surface 37 of the heat transfer element 14 and the blood also govern the heat transfer rate between the working fluid and the interior surface 38 of the heat transfer element 14. The heat transfer characteristics of the interior surface 38 are particularly important when using water, saline or other fluid that remains a liquid as the working fluid. Other coolants such as Freon undergo nucleate boiling and create mixing through a different mechanism. Saline is a safe working fluid, because it is non-toxic, and leakage of saline does not result in a gas embolism, which could occur with the use of boiling refrigerants. Since mixing in the working fluid is enhanced by the shape of the interior surface 38 of the heat transfer element 14, the working fluid can be delivered to the cooling element 14 at a warmer temperature and still achieve the necessary cooling rate. Similarly, since mixing in the working fluid is enhanced by the shape of the interior surface of the heat transfer element, the working fluid can be delivered to the warming element 14 at a cooler temperature and still achieve the necessary warming rate.
This has a number of beneficial implications in the need for insulation along the catheter shaft length. Due to the decreased need for insulation, the catheter shaft diameter can be made smaller. The enhanced heat transfer characteristics of the interior surface of the heat transfer element 14 also allow the working fluid to be delivered to the heat transfer element 14 at lower flow rates and lower pressures. High pressures may make the heat transfer element stiff and cause it to push against the wall of the blood vessel, thereby shielding part of the exterior surface 37 of the heat transfer element 14 from the blood. Because of the increased heat transfer characteristics achieved by the alternating helical ridges 28, 32, 36, the pressure of the working fluid may be as low as 5 atmospheres, 3 atmospheres, 2 atmospheres or even less than 1 atmosphere.
Referring back to
Method of Use
The practice of the present invention is illustrated in the following non-limiting example.
Of course, the use of the superior vena cava is only exemplary. It is envisioned that the following veins may be appropriate to percutaneously insert the heat transfer element: femoral, internal jugular, subclavian, and other veins of similar size and position. It is also envisioned that the following veins may be appropriate in which to dispose the heat transfer element during use: inferior vena cava, superior vena cava, femoral, internal jugular, and other veins of similar size and position. Arteries may also be employed if a fever therapy selective to a particular organ or region of the body is desired.
In some cases, a heating blanket may be used. The heating blanket serves several purposes. By warming the patient, vasoconstriction is avoided. The patient is also made more comfortable. For example, it is commonly agreed that for every one degree of core body temperature reduction, the patient will continue to feel comfortable if the same experiences a rise in surface area (skin) temperature of five degrees. Spasms due to total body hypothermia may be avoided. Temperature control of the patient may be more conveniently performed as the physician has another variable (the amount of heating) which may be adjusted.
As an alternative, the warming element may be any of the heating methods proposed in U.S. patent application Ser. No. 09/292,532, filed on Apr. 15, 1999, and entitled “Isolated Selective Organ Cooling Method and Apparatus,” and incorporated by reference above.
Anti-shivering drugs may be used to provide the features of the heating blanket. In this connection, meperidine is an analgesic of the phenyl piperdine class that is known to bind to the opiate receptor. Meperidine may be used to treat shivering due to post-operative anesthesia as well as hypothermia induced in a fever suppression treatment.
In a method according to an embodiment of the invention for treating patients with fever, the heat transfer element as described may be placed in any of several veins, including the femoral, the IVC, the SVC, the subclavian, the braichiocephalic, the jugular, and other such veins. The heat transfer element may also be placed in appropriate arteries for more selective fever reduction.
The amount of cooling performed may be judged to a first approximation by the rate of cool-down. The amount of cooling is proportional to the difference between the temperature of the blood and the temperature of the heat transfer element or cooling element. Thus, if the temperature of the blood is 40° C. and the temperature of the cooling element is 5° C., the power extracted will be greater than if the temperature of the blood is 38° C. and the temperature of the cooling element is maintained at 5° C. Thus, the cool-down or cooling rate is generally greatest at the beginning of a cooling procedure. Once the patient temperature begins to approach the target temperature, usually normothermia or 37° C., the cooling rate may be reduced because the temperature differential is no longer as great.
In any case, once the patient reaches the normothermic temperature, it is no longer easy to guess whether, in the absence of the cooling therapy, the patient would otherwise be feverish or whether the fever has abated. One embodiment of the invention allows a determination of this.
First, it is noted that the power extracted can be calculated from the temperature differential between the working fluid supply temperature and the working fluid return temperature. In particular:
Pcatheter=M cfΔTf
Where Pcatheter is the power extracted, M is the mass flow rate of the working fluid, cf is the heat capacity of the working fluid, and ΔT is the temperature differential between the working fluid as it enters the catheter and as it exits the catheter. Accordingly, Pcatheter can be readily calculated by measuring the mass flow of the circulating fluid and the temperature difference between the working fluid as it enters and exits the catheter. The power removed by the catheter as determined above may be equated to a close approximation to the power that is lost by the patient's body.
In general, a closed-form solution for the power P required to cool (or heat) a body at temperature T to temperature T0 is not known. One possible approximation may be to assume an exponential relationship:
P=α(expβ(T−To)−1)
Taking the derivative of each side with respect to temperature:
and taking the inverse of each side:
where ΔT is the temperature differential from nominal temperature and ΔP is the measured power.
A close approximation may be obtained by assuming the relationship is linear. Equivalently, a power series expansion may be taken, and the linear term retained. In any case, integrating, assuming a linear relationship, and rearranging: P=α(T−T0), where the constant of proportionality has units of watts/degree Celsius. One can determine the constant of proportionality a using two points during the therapy when both T and P are finite and known. One may be when therapy begins, i.e., when the patient has temperature T and the catheter is drawing power P. Another point may be obtained when T=T0 and P=P0.
Then, for any P, T is given by:
An example of this may be seen in
A catheter with a heat transfer element thereon may be inserted (step 204). The initial power withdrawn Pstart and body temperature Tstart may be measured (step 206), and the therapy begun (step 208). The therapy continues (step 210), and P and T are periodically, continuously, or otherwise measured (step 212). The measured T is compared to the normothermic T=T0, which is usually about 37° C. (step 214). If T is greater than T0, the therapy continues (step 210). If T is less than T0, then the power P0 is measured at T=T0 (step 216). By the equations above, a constant of proportionality a may be uniquely determined (step 218) by knowledge of Tstart, Pstart, P0, and T0. From α, Tstart, Pstart, P0, and T0, Tabsence of cooling may be determined (step 220). Tabsence of cooling is then compared to T0 (step 222). If Tabsence of cooling>T0, then the patient is still generating enough power via their metabolism to cause a fever if the therapy were discontinued. Thus, therapy is continued (step 224). If Tabsence of cooling<=T0, then the patient is no longer generating enough power via their metabolism to cause a fever if the therapy were discontinued. Thus, therapy is discontinued (step 226). Variations of the above method will be apparent to those of ordinary skill in the art.
While the invention herein disclosed is capable of obtaining the objects hereinbefore stated, it is to be understood that this disclosure is merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended other than as described in the appended claims.
This is a continuation patent application of co-pending U.S. patent application Ser. No. 10/005,416 filed on Nov. 7, 2001, now U.S. Pat. No. 6,585,752, entitled “Fever Regulation Method and Apparatus”, which is a continuation-in-part of U.S. patent application Ser. Nos: 60/246,620, filed Nov. 7, 2000, entitled “Fever Regulation Method And Apparatus”; 09/586,000, filed Jun. 2, 2000, entitled “Method For Determining The Effective Thermal Mass Of A Body Or Organ Using A Cooling Catheter”, now U.S. Pat. No. 6,383,210; and 09/566,531, filed May 8, 2000, now abandoned entitled “Method Of Making Selective Organ Cooling Catheter”, which is a continuation of U.S. patent application Ser. No. 09/103,342, filed on Jun. 23, 1998, entitled “Selective Organ Cooling Catheter And Method Of Using The Same”, now U.S. Pat. No. 6,096,068, which is a continuation-in-part of U.S. patent application Ser. No. 09/047,012, filed Mar. 24, 1998, entitled “Selective Organ Hypothermia Method And Apparatus”, now U.S. Pat. No. 5,957,963, which is a continuation-in-part of U.S. patent application Ser. No. 09/012,287, filed Jan. 23, 1998, entitled “Selective Organ Hypothermia Method And Apparatus”, now U.S. Pat. No. 6,051,019, all of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
1011606 | Fulton | Dec 1911 | A |
2148541 | Dierker | Feb 1939 | A |
2308484 | Auzin et al. | Jan 1943 | A |
2374609 | McCollum | Apr 1945 | A |
2466042 | Reich | Apr 1949 | A |
2615686 | Davidson | Oct 1952 | A |
2672032 | Towse | Mar 1954 | A |
2913009 | Kuthe | Nov 1959 | A |
3125096 | Antiles et al. | Mar 1964 | A |
3298371 | Lee | Jan 1967 | A |
3425419 | Dato | Feb 1969 | A |
3460538 | Armstrong | Aug 1969 | A |
3504674 | Swenson et al. | Apr 1970 | A |
3604419 | Diskin et al. | Sep 1971 | A |
3612175 | Ford et al. | Oct 1971 | A |
3768484 | Gawura | Oct 1973 | A |
3839621 | Hariu | Oct 1974 | A |
3865116 | Brooks | Feb 1975 | A |
3888259 | Miley | Jun 1975 | A |
3971383 | Van Gerven | Jul 1976 | A |
4038519 | Foucras | Jul 1977 | A |
4127365 | Martin et al. | Nov 1978 | A |
4153048 | Magrini | May 1979 | A |
4160455 | Law | Jul 1979 | A |
4165206 | Martin et al. | Aug 1979 | A |
4190033 | Foti | Feb 1980 | A |
4216767 | Aoshiro | Aug 1980 | A |
4231425 | Engstrom | Nov 1980 | A |
4241729 | Aoshiro | Dec 1980 | A |
4275734 | Mitchiner | Jun 1981 | A |
4298006 | Parks | Nov 1981 | A |
4318722 | Altman | Mar 1982 | A |
4323071 | Simpson et al. | Apr 1982 | A |
4375941 | Child | Mar 1983 | A |
4427009 | Wells et al. | Jan 1984 | A |
4445500 | Osterholm | May 1984 | A |
4464172 | Lichtenstein | Aug 1984 | A |
4483341 | Witteles | Nov 1984 | A |
4484586 | McMickle et al. | Nov 1984 | A |
4493625 | Pieters | Jan 1985 | A |
4497890 | Helbert | Feb 1985 | A |
4502286 | Okada et al. | Mar 1985 | A |
4569355 | Bitterly | Feb 1986 | A |
4581017 | Sahota | Apr 1986 | A |
4585056 | Oscarsson | Apr 1986 | A |
4602642 | O'Hara | Jul 1986 | A |
4638436 | Badger et al. | Jan 1987 | A |
4655746 | Daniels et al. | Apr 1987 | A |
4672962 | Hershenson | Jun 1987 | A |
4731072 | Aid | Mar 1988 | A |
4739492 | Cochran | Apr 1988 | A |
4745922 | Taylor | May 1988 | A |
4747826 | Sassano | May 1988 | A |
4748979 | Hershenson | Jun 1988 | A |
4750493 | Brader | Jun 1988 | A |
4762129 | Bonzel | Aug 1988 | A |
4762130 | Fogarty et al. | Aug 1988 | A |
4781033 | Steyert et al. | Nov 1988 | A |
4781799 | Herbert, Jr. et al. | Nov 1988 | A |
4789000 | Aslanian | Dec 1988 | A |
4796640 | Webler | Jan 1989 | A |
4817624 | Newbower | Apr 1989 | A |
4819655 | Webler | Apr 1989 | A |
4820349 | Saab | Apr 1989 | A |
4860744 | Johnson et al. | Aug 1989 | A |
4883455 | Leonard | Nov 1989 | A |
4894164 | Polaschegg | Jan 1990 | A |
4904237 | Janese | Feb 1990 | A |
4917687 | O'Boyle | Apr 1990 | A |
4920963 | Brader | May 1990 | A |
4951677 | Crowley et al. | Aug 1990 | A |
4964409 | Tremulis | Oct 1990 | A |
4973493 | Guire | Nov 1990 | A |
4979959 | Guire | Dec 1990 | A |
5000734 | Boussignac et al. | Mar 1991 | A |
5002531 | Bonzel | Mar 1991 | A |
5014695 | Benak et al. | May 1991 | A |
5018521 | Campbell | May 1991 | A |
5019075 | Spears et al. | May 1991 | A |
5024668 | Peters et al. | Jun 1991 | A |
5041089 | Mueller et al. | Aug 1991 | A |
5046497 | Millar | Sep 1991 | A |
5078713 | Varney | Jan 1992 | A |
5089260 | Hunter et al. | Feb 1992 | A |
5092841 | Spears | Mar 1992 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5106368 | Uldall et al. | Apr 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
RE33911 | Samson et al. | May 1992 | E |
5110721 | Anaise et al. | May 1992 | A |
5112438 | Bowers | May 1992 | A |
5117822 | Laghi | Jun 1992 | A |
5147355 | Friedman et al. | Sep 1992 | A |
5149321 | Klatz et al. | Sep 1992 | A |
5150706 | Cox et al. | Sep 1992 | A |
5151100 | Abele et al. | Sep 1992 | A |
5151578 | Phillips | Sep 1992 | A |
5156151 | Imran | Oct 1992 | A |
5174285 | Fontenot | Dec 1992 | A |
5180364 | Ginsburg | Jan 1993 | A |
5180896 | Gibby et al. | Jan 1993 | A |
5190539 | Fletcher et al. | Mar 1993 | A |
5191883 | Lennox et al. | Mar 1993 | A |
5196024 | Barath | Mar 1993 | A |
5197466 | Marchosky et al. | Mar 1993 | A |
5211631 | Sheaff | May 1993 | A |
5226286 | Mo | Jul 1993 | A |
5234405 | Klatz et al. | Aug 1993 | A |
5234413 | Wonder et al. | Aug 1993 | A |
5236908 | Gruber et al. | Aug 1993 | A |
5239999 | Imran | Aug 1993 | A |
5241951 | Mason et al. | Sep 1993 | A |
5246421 | Saab | Sep 1993 | A |
5248312 | Langberg | Sep 1993 | A |
5250070 | Parodi | Oct 1993 | A |
5257977 | Eshel | Nov 1993 | A |
5264260 | Saab | Nov 1993 | A |
5267341 | Shearin | Nov 1993 | A |
5269369 | Faghri | Dec 1993 | A |
5269749 | Koturov | Dec 1993 | A |
5269758 | Taheri | Dec 1993 | A |
5279299 | Imran | Jan 1994 | A |
5281213 | Milder et al. | Jan 1994 | A |
5281215 | Milder | Jan 1994 | A |
5284423 | Holdsworth et al. | Feb 1994 | A |
5295949 | Hathaway | Mar 1994 | A |
5306261 | Alliger et al. | Apr 1994 | A |
5310440 | Zingher | May 1994 | A |
D347890 | Eads | Jun 1994 | S |
D348101 | Poli et al. | Jun 1994 | S |
5320503 | Davis | Jun 1994 | A |
5322514 | Steube et al. | Jun 1994 | A |
5322515 | Karas et al. | Jun 1994 | A |
5322518 | Schneider et al. | Jun 1994 | A |
5324319 | Mason et al. | Jun 1994 | A |
5326165 | Walthall et al. | Jul 1994 | A |
5326166 | Walthall et al. | Jul 1994 | A |
5326236 | Kramer et al. | Jul 1994 | A |
5328461 | Utterberg | Jul 1994 | A |
5330435 | Vaillancourt | Jul 1994 | A |
5330438 | Gollobin et al. | Jul 1994 | A |
5330519 | Mason et al. | Jul 1994 | A |
5331309 | Sakai | Jul 1994 | A |
5332399 | Grabenkort et al. | Jul 1994 | A |
5334179 | Poli et al. | Aug 1994 | A |
5334180 | Adolf et al. | Aug 1994 | A |
5334182 | Simons et al. | Aug 1994 | A |
5334188 | Inoue et al. | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5334197 | Kriesel et al. | Aug 1994 | A |
5336190 | Moss et al. | Aug 1994 | A |
5339511 | Bell | Aug 1994 | A |
5340290 | Clemens | Aug 1994 | A |
5342181 | Schock et al. | Aug 1994 | A |
5342182 | Montoya et al. | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5342346 | Honda et al. | Aug 1994 | A |
5342347 | Kikuchi et al. | Aug 1994 | A |
5342621 | Eury | Aug 1994 | A |
5343734 | Maeda et al. | Sep 1994 | A |
5344436 | Fontenot et al. | Sep 1994 | A |
5344740 | Iwasawa et al. | Sep 1994 | A |
5346466 | Yerlikaya et al. | Sep 1994 | A |
5352213 | Woodard | Oct 1994 | A |
5354186 | Murtuza et al. | Oct 1994 | A |
5354264 | Bae et al. | Oct 1994 | A |
5354272 | Swendson et al. | Oct 1994 | A |
5358486 | Saab | Oct 1994 | A |
5364364 | Kasvikis et al. | Nov 1994 | A |
5365750 | Greenthal | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5383854 | Safar et al. | Jan 1995 | A |
5383918 | Panetta | Jan 1995 | A |
5395311 | Andrews | Mar 1995 | A |
5395314 | Klatz et al. | Mar 1995 | A |
5395331 | O'Neill et al. | Mar 1995 | A |
5403281 | O'Neill et al. | Apr 1995 | A |
5405371 | Augustine et al. | Apr 1995 | A |
5417686 | Peterson et al. | May 1995 | A |
5423745 | Todd et al. | Jun 1995 | A |
5423807 | Milder | Jun 1995 | A |
5433740 | Yamaguchi | Jul 1995 | A |
5437673 | Baust et al. | Aug 1995 | A |
5443456 | Alliger et al. | Aug 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5466131 | Altham et al. | Nov 1995 | A |
5472418 | Palestrant | Dec 1995 | A |
5486204 | Clifton | Jan 1996 | A |
5486208 | Ginsburg | Jan 1996 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5499973 | Saab | Mar 1996 | A |
5514094 | Anello et al. | May 1996 | A |
5520682 | Baust et al. | May 1996 | A |
5531776 | Ward et al. | Jul 1996 | A |
5536247 | Thornton | Jul 1996 | A |
5545133 | Burns et al. | Aug 1996 | A |
5545708 | Onwunaka et al. | Aug 1996 | A |
5549559 | Eshel | Aug 1996 | A |
5554119 | Harrison et al. | Sep 1996 | A |
5558644 | Boyd et al. | Sep 1996 | A |
5569195 | Saab | Oct 1996 | A |
5573532 | Chang et al. | Nov 1996 | A |
5578008 | Hara | Nov 1996 | A |
5584804 | Klatz et al. | Dec 1996 | A |
5588438 | McKown et al. | Dec 1996 | A |
5591162 | Fletcher et al. | Jan 1997 | A |
5620480 | Rudie | Apr 1997 | A |
5622182 | Jaffe | Apr 1997 | A |
5624342 | Younger | Apr 1997 | A |
5624392 | Saab | Apr 1997 | A |
5630837 | Crowley | May 1997 | A |
5643197 | Brucker et al. | Jul 1997 | A |
5647051 | Neer | Jul 1997 | A |
5653692 | Masterson et al. | Aug 1997 | A |
5676693 | LaFontaine | Oct 1997 | A |
5702234 | Pieters | Dec 1997 | A |
5709654 | Klatz et al. | Jan 1998 | A |
5713941 | Robins et al. | Feb 1998 | A |
5716386 | Ward et al. | Feb 1998 | A |
5730720 | Sites et al. | Mar 1998 | A |
5733318 | Augustine | Mar 1998 | A |
5733319 | Neilson et al. | Mar 1998 | A |
5735809 | Gorsuch | Apr 1998 | A |
5797878 | Bleam | Aug 1998 | A |
5799661 | Boyd et al. | Sep 1998 | A |
5800480 | Augustine et al. | Sep 1998 | A |
5800483 | Vought | Sep 1998 | A |
5800486 | Thome et al. | Sep 1998 | A |
5800488 | Crockett | Sep 1998 | A |
5800493 | Stevens et al. | Sep 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5807391 | Wijkamp | Sep 1998 | A |
5820593 | Safar et al. | Oct 1998 | A |
5824030 | Yang et al. | Oct 1998 | A |
5827222 | Klatz et al. | Oct 1998 | A |
5827237 | Macoviak et al. | Oct 1998 | A |
5827269 | Saadat | Oct 1998 | A |
5833671 | Macoviak et al. | Nov 1998 | A |
5833673 | Ockuly et al. | Nov 1998 | A |
5834465 | Olney | Nov 1998 | A |
5837003 | Ginsburg | Nov 1998 | A |
5861021 | Thome et al. | Jan 1999 | A |
5868735 | Lafontaine | Feb 1999 | A |
5871468 | Kramer et al. | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5873835 | Hastings et al. | Feb 1999 | A |
5879316 | Safar et al. | Mar 1999 | A |
5879329 | Ginsburg | Mar 1999 | A |
5891094 | Masterson et al. | Apr 1999 | A |
5899898 | Arless et al. | May 1999 | A |
5899899 | Arless et al. | May 1999 | A |
5902268 | Saab | May 1999 | A |
5906588 | Safar et al. | May 1999 | A |
5906594 | Scarfone et al. | May 1999 | A |
5906636 | Casscells, III et al. | May 1999 | A |
5910104 | Dobak, III et al. | Jun 1999 | A |
5913856 | Chia et al. | Jun 1999 | A |
5913885 | Klatz et al. | Jun 1999 | A |
5913886 | Soloman | Jun 1999 | A |
5916242 | Schwartz | Jun 1999 | A |
5957917 | Doiron et al. | Sep 1999 | A |
5957963 | Dobak, III | Sep 1999 | A |
5964751 | Amplatz et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5968009 | Simán | Oct 1999 | A |
5971979 | Joye et al. | Oct 1999 | A |
5989238 | Ginsburg | Nov 1999 | A |
6007692 | Herbert et al. | Dec 1999 | A |
6011995 | Guglielmi et al. | Jan 2000 | A |
6019783 | Philips et al. | Feb 2000 | A |
6022336 | Zadno-Azizi et al. | Feb 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6033383 | Ginsburg | Mar 2000 | A |
6042559 | Dobak, III | Mar 2000 | A |
6051019 | Dobak, III | Apr 2000 | A |
6063101 | Jacobsen et al. | May 2000 | A |
6096068 | Dobak, III et al. | Aug 2000 | A |
6106518 | Wittenberger et al. | Aug 2000 | A |
6110168 | Ginsburg | Aug 2000 | A |
6126684 | Gobin et al. | Oct 2000 | A |
6146411 | Noda et al. | Nov 2000 | A |
6146814 | Millet | Nov 2000 | A |
6149670 | Worthen et al. | Nov 2000 | A |
6149673 | Ginsburg | Nov 2000 | A |
6149676 | Ginsburg | Nov 2000 | A |
6149677 | Dobak, III | Nov 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6165207 | Balding et al. | Dec 2000 | A |
6182666 | Dobak, III | Feb 2001 | B1 |
6190354 | Sell et al. | Feb 2001 | B1 |
6194899 | Ishihara et al. | Feb 2001 | B1 |
6206004 | Schmidt et al. | Mar 2001 | B1 |
6224624 | Lasheras et al. | May 2001 | B1 |
6231594 | Dae | May 2001 | B1 |
6231595 | Dobak, III | May 2001 | B1 |
6235048 | Dobak, III | May 2001 | B1 |
6238428 | Werneth et al. | May 2001 | B1 |
6245095 | Dobak, III et al. | Jun 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6251129 | Dobak, III et al. | Jun 2001 | B1 |
6251130 | Dobak, III et al. | Jun 2001 | B1 |
6254626 | Dobak, III et al. | Jul 2001 | B1 |
6261312 | Dobak, III et al. | Jul 2001 | B1 |
6264679 | Keller et al. | Jul 2001 | B1 |
6277143 | Klatz et al. | Aug 2001 | B1 |
6287326 | Pecor | Sep 2001 | B1 |
6290697 | Tu et al. | Sep 2001 | B1 |
6290717 | Philips | Sep 2001 | B1 |
6295990 | Lewis et al. | Oct 2001 | B1 |
6299599 | Pham et al. | Oct 2001 | B1 |
6303156 | Ferrigno | Oct 2001 | B1 |
6306161 | Ginsburg | Oct 2001 | B1 |
6312374 | von Hoffmann | Nov 2001 | B1 |
6312452 | Dobak, III et al. | Nov 2001 | B1 |
6315754 | Daoud et al. | Nov 2001 | B1 |
6315995 | Pinsky et al. | Nov 2001 | B1 |
6316403 | Pinsky et al. | Nov 2001 | B1 |
6319248 | Nahon | Nov 2001 | B1 |
6325818 | Werneth | Dec 2001 | B1 |
6336911 | Westerbeck | Jan 2002 | B1 |
6338727 | Noda et al. | Jan 2002 | B1 |
6354099 | Bieberich | Mar 2002 | B1 |
6355029 | Joye et al. | Mar 2002 | B1 |
6364899 | Dobak, III | Apr 2002 | B1 |
6368304 | Aliberto et al. | Apr 2002 | B1 |
6379378 | Werneth et al. | Apr 2002 | B1 |
6383210 | Magers et al. | May 2002 | B1 |
6393320 | Lasersohn et al. | May 2002 | B1 |
6405080 | Lasersohn et al. | Jun 2002 | B1 |
6409747 | Gobin et al. | Jun 2002 | B1 |
6416533 | Gobin et al. | Jul 2002 | B1 |
6419643 | Shimada et al. | Jul 2002 | B1 |
6428563 | Keller | Aug 2002 | B1 |
6432102 | Joye et al. | Aug 2002 | B1 |
6432124 | Worthen et al. | Aug 2002 | B1 |
6436130 | Philips et al. | Aug 2002 | B1 |
6436131 | Ginsburg | Aug 2002 | B1 |
6447474 | Balding | Sep 2002 | B1 |
6450987 | Kramer | Sep 2002 | B1 |
6450990 | Walker et al. | Sep 2002 | B1 |
6451045 | Walker et al. | Sep 2002 | B1 |
6454792 | Noda et al. | Sep 2002 | B1 |
6454793 | Evans et al. | Sep 2002 | B1 |
6458150 | Evans et al. | Oct 2002 | B1 |
6460544 | Worthen | Oct 2002 | B1 |
6461347 | von Hoffmann | Oct 2002 | B1 |
6464716 | Dobak, III et al. | Oct 2002 | B1 |
6468296 | Dobak, III et al. | Oct 2002 | B1 |
6471717 | Dobak, III et al. | Oct 2002 | B1 |
6475231 | Dobak, III et al. | Nov 2002 | B1 |
6478811 | Dobak, III et al. | Nov 2002 | B1 |
6478812 | Dobak, III et al. | Nov 2002 | B1 |
6482226 | Dobak, III | Nov 2002 | B1 |
20010001830 | Dobak, III et al. | May 2001 | A1 |
20010001831 | Dobak, III et al. | May 2001 | A1 |
20010001832 | Dobak, III et al. | May 2001 | A1 |
20010002442 | Dobak, III | May 2001 | A1 |
20010005791 | Ginsburg et al. | Jun 2001 | A1 |
20010007951 | Dobak, III | Jul 2001 | A1 |
20010008975 | Dobak, III et al. | Jul 2001 | A1 |
20010009610 | Augustine et al. | Jul 2001 | A1 |
20010010011 | Aliberto et al. | Jul 2001 | A1 |
20010011184 | Dobak, III et al. | Aug 2001 | A1 |
20010011185 | Dobak, III et al. | Aug 2001 | A1 |
20010014802 | Tu | Aug 2001 | A1 |
20010016763 | Lasheras et al. | Aug 2001 | A1 |
20010016764 | Dobak, III | Aug 2001 | A1 |
20010021865 | Dobak, III et al. | Sep 2001 | A1 |
20010021866 | Dobak, III et al. | Sep 2001 | A1 |
20010027333 | Schwartz | Oct 2001 | A1 |
20010029394 | Dobak, III et al. | Oct 2001 | A1 |
20010031946 | Walker et al. | Oct 2001 | A1 |
20010032003 | Pecor | Oct 2001 | A1 |
20010032004 | Werneth | Oct 2001 | A1 |
20010039440 | Lasheras et al. | Nov 2001 | A1 |
20010041923 | Dobak, III | Nov 2001 | A1 |
20010044644 | Keller et al. | Nov 2001 | A1 |
20010047191 | Lasersohn et al. | Nov 2001 | A1 |
20010047192 | Lasersohn et al. | Nov 2001 | A1 |
20010047196 | Ginsburg et al. | Nov 2001 | A1 |
20010049545 | Lasersohn et al. | Dec 2001 | A1 |
20020002394 | Dobak, III | Jan 2002 | A1 |
20020004675 | Lasheras | Jan 2002 | A1 |
20020007179 | Dobak, III et al. | Jan 2002 | A1 |
20020007202 | Dobak, III et al. | Jan 2002 | A1 |
20020007203 | Gilmartin et al. | Jan 2002 | A1 |
20020016621 | Werneth et al. | Feb 2002 | A1 |
20020022823 | Luo et al. | Feb 2002 | A1 |
20020026227 | Philips | Feb 2002 | A1 |
20020029016 | Pham et al. | Mar 2002 | A1 |
20020032430 | Luo et al. | Mar 2002 | A1 |
20020032474 | Dobak, III et al. | Mar 2002 | A1 |
20020040717 | Dobak, III | Apr 2002 | A1 |
20020045852 | Saab | Apr 2002 | A1 |
20020045892 | Kramer | Apr 2002 | A1 |
20020045925 | Keller et al. | Apr 2002 | A1 |
20020049409 | Noda et al. | Apr 2002 | A1 |
20020049410 | Noda et al. | Apr 2002 | A1 |
20020049484 | Werneth et al. | Apr 2002 | A1 |
20020056281 | Bieberich | May 2002 | A1 |
20020066458 | Aliberto et al. | Jun 2002 | A1 |
20020068901 | Werneth | Jun 2002 | A1 |
20020068964 | Dobak, III | Jun 2002 | A1 |
20020077665 | Kordis et al. | Jun 2002 | A1 |
20020077680 | Noda | Jun 2002 | A1 |
20020082671 | Magers et al. | Jun 2002 | A1 |
20020091378 | Dobak, III et al. | Jul 2002 | A1 |
20020091429 | Dobak, III et al. | Jul 2002 | A1 |
20020091430 | Dobak, III et al. | Jul 2002 | A1 |
20020095198 | Whitebook et al. | Jul 2002 | A1 |
20020095200 | Dobak, III et al. | Jul 2002 | A1 |
20020095201 | Worthen et al. | Jul 2002 | A1 |
20020099427 | Dobak, III | Jul 2002 | A1 |
20020103519 | Dobak, III et al. | Aug 2002 | A1 |
20020111584 | Walker et al. | Aug 2002 | A1 |
20020111616 | Dea et al. | Aug 2002 | A1 |
20020111657 | Dae et al. | Aug 2002 | A1 |
20020116039 | Walker et al. | Aug 2002 | A1 |
20020116041 | Daoud | Aug 2002 | A1 |
20020120314 | Evans et al. | Aug 2002 | A1 |
20020128698 | Dobak, III et al. | Sep 2002 | A1 |
20020138122 | Worthen et al. | Sep 2002 | A1 |
20000151943 | Balding | Oct 2002 | |
20020151845 | Werneth | Oct 2002 | A1 |
20020151942 | Walker et al. | Oct 2002 | A1 |
20020151944 | Walker et al. | Oct 2002 | A1 |
20020151945 | Gobin et al. | Oct 2002 | A1 |
20020151946 | Dobak, III | Oct 2002 | A1 |
20020156421 | Noda et al. | Oct 2002 | A1 |
20020156469 | Yon et al. | Oct 2002 | A1 |
20020161331 | Noda et al. | Oct 2002 | A1 |
20020169489 | Dobak, III et al. | Nov 2002 | A1 |
20020169490 | Noda et al. | Nov 2002 | A1 |
20020173834 | Noda et al. | Nov 2002 | A1 |
Number | Date | Country |
---|---|---|
685559 | Jan 1998 | AU |
730835 | Mar 2001 | AU |
739996 | Oct 2001 | AU |
734506 | Nov 2001 | AU |
743945 | Feb 2002 | AU |
748985 | Jun 2002 | AU |
2177982 | Jun 1995 | CA |
1082382 | Feb 1994 | CN |
6555225 | May 1993 | EP |
0664990 | Nov 1997 | EP |
0 428 505 | Mar 2001 | EP |
1172932 | Jul 2001 | EP |
1205167 | May 2002 | EP |
1029520 | Aug 2002 | EP |
2447406 | Nov 1981 | FR |
806 029 | Feb 1981 | SU |
WO 9105528 | May 1991 | WO |
WO 9304727 | Mar 1993 | WO |
WO 9501814 | Jan 1995 | WO |
WO 9640347 | Dec 1996 | WO |
WO 9701374 | Jan 1997 | WO |
WO 9725011 | Jul 1997 | WO |
WO 9732518 | Sep 1997 | WO |
WO 9732818 | Sep 1997 | WO |
WO 9826831 | Jun 1998 | WO |
WO 9831312 | Jul 1998 | WO |
WO 9849957 | Nov 1998 | WO |
WO 9902096 | Jan 1999 | WO |
WO 9904211 | Jan 1999 | WO |
WO 9937226 | Jul 1999 | WO |
WO 9944519 | Sep 1999 | WO |
WO 9948449 | Sep 1999 | WO |
WO 9956812 | Nov 1999 | WO |
WO 9966970 | Dec 1999 | WO |
WO 9966971 | Dec 1999 | WO |
WO 9909054 | Feb 2000 | WO |
WO 0010494 | Mar 2000 | WO |
WO 0038601 | Jul 2000 | WO |
WO 0047145 | Aug 2000 | WO |
WO 0048670 | Aug 2000 | WO |
WO 0051534 | Sep 2000 | WO |
WO 0053135 | Sep 2000 | WO |
WO 0053246 | Sep 2000 | WO |
WO 0057823 | Oct 2000 | WO |
WO 0062837 | Oct 2000 | WO |
WO 0066053 | Nov 2000 | WO |
WO 0072779 | Dec 2000 | WO |
WO 0072787 | Dec 2000 | WO |
WO 0103606 | Jan 2001 | WO |
WO 0108580 | Feb 2001 | WO |
WO 0110323 | Feb 2001 | WO |
WO 0110365 | Feb 2001 | WO |
WO 0112061 | Feb 2001 | WO |
WO 0112122 | Feb 2001 | WO |
WO 0113809 | Mar 2001 | WO |
WO 0113837 | Mar 2001 | WO |
WO 0117471 | Mar 2001 | WO |
WO 0119447 | Mar 2001 | WO |
WO 0126590 | Apr 2001 | WO |
WO 0130413 | Apr 2001 | WO |
WO 0141708 | Jun 2001 | WO |
WO 0143661 | Jun 2001 | WO |
WO 0149236 | Jul 2001 | WO |
WO 0152781 | Jul 2001 | WO |
WO 0156517 | Aug 2001 | WO |
WO 0158397 | Aug 2001 | WO |
WO 0164145 | Sep 2001 | WO |
WO 0164146 | Sep 2001 | WO |
WO 0174276 | Oct 2001 | WO |
WO 0176655 | Oct 2001 | WO |
WO 0178580 | Oct 2001 | WO |
WO 0187174 | Nov 2001 | WO |
WO 0187379 | Nov 2001 | WO |
WO 0195840 | Dec 2001 | WO |
WO 0207793 | Jan 2002 | WO |
WO 0219934 | Mar 2002 | WO |
WO 0226175 | Apr 2002 | WO |
WO 0226176 | Apr 2002 | WO |
WO 0226285 | Apr 2002 | WO |
WO 0226307 | Apr 2002 | WO |
WO 0228300 | Apr 2002 | WO |
WO 0236180 | May 2002 | WO |
WO 0238091 | May 2002 | WO |
WO 0243577 | Jun 2002 | WO |
WO 0247577 | Jun 2002 | WO |
WO 0247742 | Jun 2002 | WO |
WO 02055129 | Jul 2002 | WO |
WO 02056938 | Jul 2002 | WO |
WO 02058606 | Aug 2002 | WO |
WO 02060514 | Aug 2002 | WO |
WO 02065941 | Aug 2002 | WO |
WO 02069862 | Sep 2002 | WO |
WO 02080810 | Oct 2002 | WO |
Number | Date | Country | |
---|---|---|---|
20030187489 A1 | Oct 2003 | US |
Number | Date | Country | |
---|---|---|---|
60246620 | Nov 2000 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10005416 | Nov 2001 | US |
Child | 10411001 | US | |
Parent | 09103342 | Jun 1998 | US |
Child | 09566531 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09586000 | Jun 2000 | US |
Child | 10005416 | US | |
Parent | 09566531 | May 2000 | US |
Child | 09586000 | US | |
Parent | 09047012 | Mar 1998 | US |
Child | 09103342 | US | |
Parent | 09012287 | Jan 1998 | US |
Child | 09047012 | US |